No single strain or vector is capable of being the best expression option for all types of biopharmaceuticals. Therefore, Lonza has assembled a collection of proprietary expression systems to address the diversity of microbially derived proteins. Our XS Technology™ Platform has shown expression levels in excess of 19 g/L.
Scientists face many expression challenges including inclusion bodies, low expression levels, and product instability. Lonza has created a rationally designed experimental process to identify the best production choice for the product of interest. This unique toolbox of experimental options includes a selection of host organisms, plasmids, promoters, selection markers, signal sequences, translational initiation regions, and stabilizing elements. Following initial strain design, samples are immediately screened using a variety of analytical techniques including SDS PAGE, Western Blot, Dot Blot, ELISA Assays, biolayer interferometry and capillary electrophoresis. Depending on the host organism, final strain selection is achieved within 6 to 8 weeks, starting from synthesized gene through to final production strain.
Case studies will be presented on use of the XS tool box to address common problems such as:
- Low Productivity
- Product-related impurities
- Plasmid and Host Instability
The Lonza XS System™ ultimately decreases the time of strain screening and design to enable the fast creation of a valuable production strain and efficient cGMP process.